Metallocompounds are a class of anticancer compounds largely used in the treatment of several types of solid tumors, including bone cancer. Osteosarcoma (OS) is a primary malignant bone tumor that frequently affects children, adolescents and young adults. It is a very invasive type of tumor, so ∼40% of patients develop distant metastases, showing elevated mortality rates. In this review, we present an outline of the chemistry and antitumor properties of metal-based compounds in preclinical (in vitro and in vivo) and clinical OS models, focusing on the relationship between structure-activity, molecular targets and the study of the mechanism of action involved in metallocompound anticancer activity.
Keyphrases
- end stage renal disease
- bone mineral density
- newly diagnosed
- ejection fraction
- young adults
- papillary thyroid
- lymph node
- soft tissue
- cardiovascular events
- bone loss
- type diabetes
- squamous cell
- cardiovascular disease
- patient reported outcomes
- cell therapy
- bone regeneration
- single molecule
- patient reported
- lymph node metastasis